Keytruda, talazoparib join I-SPY 2

QuantumLeap Healthcare Collaborative said it is adding two new treatment arms to the ongoing, adaptive Phase II I-SPY 2 trial, which is testing therapies to treat patients with hormone receptor (HR)-negative, HER2-positive and HR-negative/HER2-positive breast cancer.

A treatment arm evaluating Keytruda pembrolizumab, a humanized IgG4 mAb against PD-1, from Merck & Co. Inc. (NYSE:MRK), has already begun. QuantumLeap said a second arm to evaluate talazoparib (MDV3800, formerly BMN 673), a poly(ADP-ribose) polymerase ( PARP) inhibitor from Medivation Inc. (NASDAQ:MDVN), is to begin "in the next few months." The talazoparib arm will be the first in I-SPY 2 to test a regimen without paclitaxel. ...